Market research
KALA Kala Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 16M
- P/E ratio
- Not available
- Analyst target
- 1.5
- Dividend yield
- Not available
- Beta
- -2.28
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US4831193010
- Market cap
- 16M
- P/E ratio
- Not available
- Analyst target
- 1.5
- Dividend yield
- Not available
- Beta
- -2.28
About
About Kala Pharmaceuticals Inc
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the KALA discussion.
5 years, 4 months ago
Kala Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 35.3% below its 200 day moving average.
From a valuation standpoint, the stock is 95.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 58.5.
Kala Pharmaceuticals, Inc's total revenue rose by 89.7% to $2M since the same quarter in the previous year.
Its net income has dropped by 41.7% to $-31M since the same quarter in the previous year.
Finally, its free cash flow fell by 43.5% to $-26M since the same quarter in the previous year.
Based on the above factors, Kala Pharmaceuticals, Inc gets an overall score of 2/5.